Merck KGaA drops $1.3B on U.K. gene-silencing biotech for rare-disease bet
All-cash acquisition delivers divesiran, a late-stage-ready experimental treatment, to Merck KGaA's pipeline.
By Abdullah Al-Otaibi·· 3 min

Loading the Newsroom
Curating from trusted global sources…
1 briefing · “pipeline”
All-cash acquisition delivers divesiran, a late-stage-ready experimental treatment, to Merck KGaA's pipeline.